Tris Pharma Achieves Significant Milestone with Non-Opioid Painkiller Cebranopadol in Phase III Trials
Cebranopadol's Efficacy and Safety:
Cebranopadol, a dual-NMR agonist, has shown strong efficacy and a solid safety profile in Phase III trials, particularly in the ALLEVIATE-1 trial, where it demonstrated a statistically significant drop in pain intensity 44 hours post-operation in patients who underwent abdominoplasty4.
Reduced Abuse Potential:
The drug has been found to have significantly less potential for abuse compared to traditional opioids like tramadol and oxycodone, as indicated by its lower likeability in nondependent recreational opioid users2.
Mechanism of Action:
Cebranopadol works by targeting both the nociceptin/orphanin FQ peptide (NOP) receptor and the µ-opioid peptide (MOP) receptor, offering a novel mechanism that mimics the body’s natural pain-modulation processes5.
Development and Future Plans:
Tris Pharma is conducting further Phase III trials, including one in bunionectomy patients, with an NDA submission expected later in 20254.
Addressing Unmet Needs:
The development of cebranopadol aims to address the significant unmet needs in pain management, particularly for patients who require effective and safe alternatives to traditional opioids35.
Sources:
2. https://www.trispharma.com/tris-pharma-reports-positive-topline-data-from-clinical-study-of-investigational-pain-therapy-cebranopadol-showing-significantly-less-potential-for-abuse-versus-tramadol-and-oxycodone/
3. https://www.trispharma.com/tris-pharma-announces-acquisition-of-new-late-stage-drug-candidate-for-pain/
4. https://www.biospace.com/drug-development/tris-pharma-records-late-stage-win-for-non-opioid-painkiller